Harmony Biosciences Holdings, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $268.9 million (+12.3% year over year) and diluted EPS of $0.81. It usually reports 12–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
269
+12.3%
|
48
-5.2%
|
0.81
-6.9%
|
|
Jul 16, 2026
16 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
261
+30.3%
|
75
+89.6%
|
1.28
+88.2%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
215
+16.6%
|
32
-28.7%
|
0.55
-29.5%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
244
+21.1%
|
22
-54.6%
|
0.39
-54.4%
|
|
Oct 23, 2025
23 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
239
+28.7%
|
51
+10.4%
|
0.87
+10.1%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
200
+16.0%
|
40
+243.2%
|
0.68
+240.0%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
185
+19.5%
|
46
+18.9%
|
0.78
+16.4%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
201
+19.5%
|
49
+85.9%
|
0.85
+87.9%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HRMY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Plymouth Meeting, PA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1802665
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.